Jeff Jonker

Senior Advisor, Ambys Medicines

Jeff Jonker is a veteran biotech executive with experience in operational, strategic, business development and legal roles across public and private companies. Mr. Jonker is a senior advisor to Ambys Medicines, where he was previously President and CEO, and other early stage biotech companies. Immediately prior to Ambys, Mr. Jonker served as President of NGM Biopharmaceuticals (NASDAQ: NGM), where he established the Merck partnership, grew the organization into a fully integrated clinical development company and guided the company’s robust pipeline, including therapeutics for immuno-oncology, retinal, liver and metabolic diseases. Prior to joining NGM, Mr. Jonker was Senior Vice President, Corporate and Business Development at Theravance Biopharma (NASDAQ: TBPH) and held that same role at Theravance, Inc. (NASDAQ: THRX) prior to completing the spin-out of TBPH and creation of Innoviva, Inc. (NASDAQ: INVA). He previously served as Chief Business Officer of Satori Pharmaceuticals, Vice President of Business Development and Corporate Strategy for Gloucester Pharmaceuticals prior to its acquisition by Celgene (NASDAQ: CELG), and in multiple leadership positions in the business development and legal groups at Genentech. Prior to Genentech, Mr. Jonker was a member of the Technology Transactions Group at Wilson, Sonsini, Goodrich & Rosati, representing clients in the life science and high tech industries. Mr. Jonker holds a J.D. from Columbia University School of Law, an M.LITT. from the University of St. Andrews and a B.A. from Claremont McKenna College.